Explore retatrutide/cagrilintide calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized retatrutide/cagrilintide calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
Retatrutide/Cagrilintide is a research-only blend most often sourced for weight-loss and metabolic studies that pair incretin and amylin pharmacology in one protocol — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist retatrutide alongside Novo Nordisk's amylin analog cagrilintide. No sponsor markets it as a fixed-ratio drug; it ships as lyophilized powder you reconstitute with bacteriostatic water before use.[1][2]
Retatrutide engages the GIP, GLP-1, and glucagon receptors to amplify glucose-dependent insulin release, slow gastric emptying, and increase resting energy expenditure via the glucagon arm. Cagrilintide engages calcitonin/amylin-receptor heterodimers (AMY1–3) in the area postrema and hypothalamic arcuate nucleus to add a second, independent satiety signal and further slow gastric emptying. The combination is therefore mechanistically complementary rather than redundant.[2]
No randomized clinical trial of the retatrutide + cagrilintide combination has been published. The two molecules are studied separately: retatrutide in the TRIUMPH Phase 3 program for obesity and T2D,[1] and cagrilintide in the REDEFINE Phase 3 program as a fixed combination with semaglutide (CagriSema).[3] Any combined dosing protocol is extrapolated from the individual single-agent data.
Neither component is FDA-approved. Both are investigational; the fixed-ratio combination is not in any sponsor pipeline. Research-grade material only.
Retatrutide/Cagrilintide has a reported half-life of ~6 days (retatrutide-driven). The pharmacokinetic reference models an interval of once weekly; this is not a measured community cadence or a dosing recommendation. Both components are long-acting (retatrutide ~6 days, cagrilintide ~7–8 days), so once-weekly dosing builds to steady state over about 5 weeks with meaningful carryover between doses. Pharmacokinetic source: Component data: Jastreboff et al. NEJM 2023 (retatrutide); cagrilintide phase 1/2. Retatrutide/Cagrilintide is a blend of Cagrilintide and Retatrutide, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Weight Loss on WPA.
289 Retatrutide/Cagrilintide reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
There is one fact that has to anchor any honest discussion of the retatrutide/cagrilintide blend: the combination has never been formally studied in a single published clinical trial. There is no shared sponsor program, no IND filing for the pair, no pivotal protocol that has tested the blend at any dose, in any cadence, in any population. The pharmacology rationale that researchers reach for when they decide to stack the two molecules is drawn entirely from two independent programs that share no overlap. From the retatrutide side that means the Phase 2 trial in NEJM (Jastreboff et al., 2023) (338 adults with obesity, 48 weeks, arms at 1 / 4 / 8 / 12mg once weekly with the 12mg arm reaching about 24% mean weight reduction) and the Phase 3 TRIUMPH program from Eli Lilly, which standardized the escalation at 2mg start with 4-week step-ups to 4mg, 8mg, and a 12mg target. From the cagrilintide side it means Lau et al., Lancet 2021 (706 adults, cagrilintide arms 0.3 / 0.6 / 1.2 / 2.4 / 4.5mg weekly, 4.5mg producing about 10.8% mean weight reduction at 26 weeks) and the CagriSema Phase 3 REDEFINE program, where a fixed 2.4mg cagrilintide + 2.4mg semaglutide pairing reported about 22.7% mean weight reduction at 68 weeks in REDEFINE 1. The biological case for combining retatrutide and cagrilintide specifically rests on the non-overlap of their receptor families: retatrutide is a GIP / GLP-1 / glucagon triple agonist, and cagrilintide is an amylin agonist — none of those four signaling pathways is shared. CagriSema is the closest published proof-of-concept that adding amylin to a GLP-1-spine molecule produces a measurable additive weight-loss effect, and the retatrutide/cagrilintide blend extends that logic by replacing the GLP-1-only spine with the most potent triple agonist currently in clinical development.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.